Search hospitals

>

Texas

>

Houston

Houston Methodist Hospital

Claim this profile

Houston, Texas 77030

Global Leader in Stroke

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Heart Failure

Conducts research for Non-Hodgkin's Lymphoma

821 reported clinical trials

101 medical researchers

Photo of Houston Methodist Hospital in HoustonPhoto of Houston Methodist Hospital in HoustonPhoto of Houston Methodist Hospital in Houston

Summary

Houston Methodist Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Stroke, Breast Cancer, Lung Cancer, Heart Failure, Non-Hodgkin's Lymphoma and other specialties. Houston Methodist Hospital is involved with conducting 821 clinical trials across 1,025 conditions. There are 101 research doctors associated with this hospital, such as Jun Zhang, Carlos Ramos, MD, Maen Abdelrahim, MD, and Rayne H. Rouce.

Area of expertise

1

Stroke

Global Leader

Houston Methodist Hospital has run 44 trials for Stroke.

2

Breast Cancer

Global Leader

Houston Methodist Hospital has run 44 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 positive
HER2 negative

Top PIs

Clinical Trials running at Houston Methodist Hospital

Ovarian Cancer

Lung Cancer

Prostate Cancer

Breast Cancer

Multiple Myeloma

Crohn's Disease

Uterine Cancer

Pancreatic Cancer

Endometrial Cancer

Non-Small Cell Lung Cancer

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Avutometinib + Defactinib

for Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Minimally Invasive Surgery vs Laparotomy After Chemotherapy

for Ovarian and Related Cancers

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. Laparotomy is a surgical procedure which allows the doctors to remove some or all of the tumor and check if the disease has spread to other organs in the body. MIS may work the same or better than standard laparotomy after chemotherapy in prolonging the return of the disease and/or improving quality of life after surgery.

Recruiting

2 awards

Phase 3

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Houston Methodist Hospital?

Where is Houston Methodist Hospital located?

Who should I call to ask about financial aid or insurance network?

What insurance does Houston Methodist Hospital accept?

What awards or recognition has Houston Methodist Hospital received?